Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:GLCCI1 polymorphism rs37973 and asthma treatment response to inhaled corticosteroids
Avtorji:Rijavec, Matija (Avtor)
Žavbi, Mateja (Avtor)
Lopert, Anton (Avtor)
Fležar, Matjaž (Avtor)
Korošec, Peter (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background. Asthma treatment response is highly variable and pharmacogenetic markers that predict treatment response would be one step closer to personalized treatment. GWAS studies have shown that polymorphisms GLCCI1 could be associated with asthma treatment response to inhaled corticosteroids (ICS). Materials and methods. We genotyped rs37973 of GLCCI1 in 208 adult asthma patients treated with ICS. Change in % predicted FEV1 was analysed after short-term (3 months) and after long-term (at least 3 years) treatment. Treatment success was defined as good when FEV1 decreased less than 30 ml/year. Results. After 3 months of treatment, change of % predicted FEV1 was higher in patients with GG genotype than in patients with AG+AA genotype, and this genotype dependent difference was only evident in non-smokers. Similar results were found after at least 3 years of treatment when all patients were analysed, in non-smokers and patients with atopy. Even though, no differences in treatment success (good vs. poor response) were observed when analysing the entire group of patients, genotype dependent treatment success was highly influenced by smoking and atopy. GG genotype was overrepresented in non-smokers and patients with atopy with good response. Conclusions. Rs37973 was associated with short- and long-term treatment response; however, there was a great influence of smoking and atopy on pharmacogenetic association. Furthermore, we found GG genotype to be associated with better treatment response, what is contrary to results found in GWAS.
Ključne besede:asthma -- diagnosis -- therapy, pharmacogenetics, genetic polymorphism, smoking, inhaled corticosteroids, atopy, GLCCI1, FEV1, rs37973
Leto izida:2018
Založnik:Esmon Publicidad
Izvor:Španija
UDK:616.2
ISSN pri članku:1698-0808
OceCobissID:524162329 Povezava se odpre v novem oknu
COBISS_ID:2048262769 Povezava se odpre v novem oknu
DOI:10.18176/jiaci.0229 Povezava se odpre v novem oknu
Opombe:Soavtorji: Žavbi M, Lopert A, Fležar M, Korošec P; Nasl. z nasl. zaslona; Opis vira z dne 21. 3. 2018;
Število ogledov:174
Število prenosov:77
Datoteke:URL URL - Izvorni URL, za dostop obiščite http://www.jiaci.org/revistas/vol28issue3_3.pdf
 
Nadgradivo:J. investig. allergol. clin. immunol.
Esmon Publicidad
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© 2018 Esmon Publicidad, S.A.
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Nazaj